GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Cyclically Adjusted PB Ratio

PLx Pharma (FRA:1D5A) Cyclically Adjusted PB Ratio : (As of Jun. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


PLx Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for PLx Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Cyclically Adjusted PB Ratio Chart

PLx Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PLx Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.07

Competitive Comparison of PLx Pharma's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Cyclically Adjusted PB Ratio falls into.



PLx Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PLx Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, PLx Pharma's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.365/125.2265*125.2265
=0.365

Current CPI (Sep. 2022) = 125.2265.

PLx Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201212 1.961 96.871 2.535
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 2.304 98.326 2.934
201403 24.113 99.695 30.288
201406 22.200 100.560 27.646
201409 20.923 100.428 26.090
201412 19.718 99.070 24.924
201503 20.269 99.621 25.479
201506 27.619 100.684 34.351
201509 24.615 100.392 30.704
201512 21.960 99.792 27.557
201603 18.379 100.470 22.908
201606 15.055 101.688 18.540
201609 12.453 101.861 15.310
201612 -1.582 101.863 -1.945
201703 9.495 102.862 11.559
201706 1.508 103.349 1.827
201709 1.175 104.136 1.413
201712 0.447 104.011 0.538
201803 0.920 105.290 1.094
201806 0.642 106.317 0.756
201809 0.333 106.507 0.392
201812 0.648 105.998 0.766
201903 -0.450 107.251 -0.525
201906 -1.331 108.070 -1.542
201909 -1.016 108.329 -1.174
201912 -1.189 108.420 -1.373
202003 -1.052 108.902 -1.210
202006 -1.589 108.767 -1.829
202009 -1.829 109.815 -2.086
202012 -0.646 109.897 -0.736
202103 1.643 111.754 1.841
202106 1.273 114.631 1.391
202109 0.956 115.734 1.034
202112 1.146 117.630 1.220
202203 0.856 121.301 0.884
202206 0.554 125.017 0.555
202209 0.365 125.227 0.365

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PLx Pharma  (FRA:1D5A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PLx Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma (FRA:1D5A) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines